Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT - Concepedia

Concepedia

Publication | Open Access

Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT

DOI Full Paper Access

18

Citations

25

References

2022

Year

Silje Agnethe Stokke Kvistad, Joachim Burman, Anne Kristine Lehmann, Andreas Tolf, Christina Zjukovskaja, Guro Kristin Melve, Lars Bø, Øivind Torkildsen

Journal of Neurology Neurosurgery & Psychiatry

Abstract

This study provides level 4 evidence that AHSCT in patients previously treated with alemtuzumab, cladribine or rituximab is safe and efficacious.

References

	Year	Citations

Page 1